undamentalytics Newsletter
Sign in

Abvc Biopharma, Inc. revenue

Abvc Biopharma, Inc.'s revenue was $296,000 in fiscal 2025, down 41.9% on the year before. Since fiscal 2010 ($14,860) it has grown at a compound 25.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue000005001001010
Growth on the year before—−78.5%+79.1%+36.3%−100.0%—−100.0%+>999%−31.2%−26.3%+172.6%−84.3%+234.3%−41.9%
Gross profit————0—−01001−01—
Gross margin———————97.1%96.1%98.6%70.5%−98.1%99.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Abvc Biopharma, Inc. $509,589 234.3% 12.7%
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Cervomed Inc. $331,295 -95.7% -52.7%
Medicinova Inc $920,481 875.7% —
Shattuck Labs, Inc. $1.0m -66.6% 5.2%
Longeveron Inc. $1.2m -42.7% 10.4%

Compare with peers

Head to head: ABVC vs CRDFABVC vs CRVOABVC vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abvc Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abvc Biopharma, Inc.